Codexis, Inc.
General ticker "CDXS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $243.2M (TTM average)
Codexis, Inc. follows the US Stock Market performance with the rate: 0.2%.
Estimated limits based on current volatility of 7.3%: low 1.01$, high 1.17$
Factors to consider:
- Earnings expected soon, date: 2026-03-11 amc
- Total employees count: 188 (+8.0%) as of 2024
- China accounted for 16.5% of revenue in the fiscal year ended 2024-12-31
- US accounted for 35.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: History of net losses and potential unprofitability, Productivity and cost issues at facilities, Third-party risks, Labor/talent shortage/retention, Strategic risks and growth management
- Current price 58.7% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.45$, 7.75$]
- 2025-12-31 to 2026-12-31 estimated range: [3.05$, 6.96$]
Financial Metrics affecting the CDXS estimates:
- Positive: with PPE of -5.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.32 <= 0.01
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Investing cash flow per share per price, % of -15.36 <= -14.22
- Positive: 42.68 < Shareholder equity ratio, % of 44.91 <= 64.29
- Negative: Industry earnings per price (median), % of -15.81 <= 0
Short-term CDXS quotes
Long-term CDXS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $138.59MM | $70.14MM | $59.34MM |
| Operating Expenses | $173.47MM | $138.21MM | $117.86MM |
| Operating Income | $-34.88MM | $-68.07MM | $-58.52MM |
| Non-Operating Income | $1.56MM | $-8.10MM | $-6.72MM |
| R&D Expense | $80.10MM | $58.88MM | $46.26MM |
| Income(Loss) | $-33.32MM | $-76.17MM | $-65.24MM |
| Taxes | $0.28MM | $0.07MM | $0.03MM |
| Profit(Loss)* | $-33.59MM | $-76.24MM | $-65.28MM |
| Stockholders Equity | $144.80MM | $86.61MM | $66.93MM |
| Inventory | $2.03MM | $2.69MM | $1.80MM |
| Assets | $250.39MM | $136.56MM | $149.01MM |
| Operating Cash Flow | $11.28MM | $-52.64MM | $-49.41MM |
| Capital expenditure | $8.31MM | $4.42MM | $4.30MM |
| Investing Cash Flow | $-13.58MM | $-4.86MM | $-56.98MM |
| Financing Cash Flow | $-0.57MM | $8.17MM | $60.52MM |
| Earnings Per Share** | $-0.51 | $-1.12 | $-0.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.